🔍

Beryl Drugs Ltd (524606)

📊 BSE: 524606 🏢 Pharmaceuticals 📢 Latest filing: 29 Sep 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Beryl Drugs' revenue was ₹7.6 Cr (+56.7% year on year, +38.3% on the previous quarter), and net profit ₹0.2 Cr; the operating margin was 8.6%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹7.6	+56.7%	+38.3%
Operating profit	₹0.6	+17.8%	-51.7%
Net profit	₹0.2	—	-60.6%
EPS (₹)	0.44	—	-60.0%
Operating margin	8.6%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Beryl Drugs Hikes Material RPT Limit with Aminova Infusions from ₹5.00 Cr to ₹8.00 Cr

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 29 Sep 2026, 11:52 AM

Shareholders of Beryl Drugs Ltd approved an ordinary resolution at the 33rd AGM on September 29, 2026, to increase the limit of material related party transactions with M/s. Aminova Infusions Pvt. Ltd. from ₹5.00 crore to ₹8.00 crore. This ₹8.00 crore ceiling applies over the unexpired period of the previously approved two-year tenure (originally granted at the EGM on May 11, 2026). Relative to the company's TTM revenue of ₹22 crore, this overall limit represents a significant portion (~36.4%), indicating substantial business reliance on this related party. Transactions will continue in the ordinary course of business and on an arm's length basis.

AGM approved hiking material related party transaction limit with Aminova Infusions from ₹5.00 crore to ₹8.00 crore
Revised ₹8.00 crore represents an overall ceiling for the originally approved 2-year tenure from the May 11, 2026 EGM
Transactions are conducted in the ordinary course of business and at arm's length
The ₹8.00 crore ceiling equals ~36.4% of Beryl Drugs' TTM revenue of ₹22 crore

💡 Track subsequent quarterly disclosures to review the actual quantum of related-party sales or purchases with Aminova Infusions and ensure transactions remain margin-neutral.

Beryl Drugs Board to Meet on Sept 2, 2026 for 33rd AGM & Related Party Limits

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 27 Aug 2026, 09:45 PM

Beryl Drugs Ltd has scheduled a Board of Directors meeting on September 2, 2026, primarily to approve the Board's Report and finalize details for its 33rd Annual General Meeting (AGM). The board will also decide on the book closure, cut-off date, and remote e-voting schedule. Additionally, the agenda includes evaluating a proposal to increase the limit of material related-party transactions with M/s Aminova Infusions Pvt. Ltd.

Board meeting scheduled on September 2, 2026 at 02:00 PM at Indore registered office.
Agenda covers approving the Board Report and Notice for the 33rd AGM.
Proposal to increase limits for material related-party transactions with M/s Aminova Infusions Pvt. Ltd.
Appointment of Dipika Kataria as Scrutinizer for remote e-voting and AGM voting.

💡 Track the board meeting outcome on September 2, 2026, particularly the quantum and terms of the proposed related-party transactions with Aminova Infusions.

₹7.57 Cr Revenue in Q1 FY27, up 166% YoY; Net Profit rises to ₹0.22 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 11 Aug 2026, 05:15 PM

Beryl Drugs reported a significant top-line expansion in Q1 FY27, with total revenue reaching ₹7.57 Cr, a 166% increase from ₹2.84 Cr in Q1 FY26. Net profit surged to ₹22.08 Lakhs compared to just ₹2.11 Lakhs in the same period last year, although it declined sequentially from ₹56.25 Lakhs in Q4 FY26. The sequential profit drop is attributed to a sharp spike in 'Other Expenses,' which rose to ₹1.86 Cr from ₹0.38 Cr in the previous quarter. Despite margin pressure, the company remains profitable with an EPS of ₹0.47 for the quarter.

Total Revenue from operations grew 166% YoY to ₹7.57 Cr, representing nearly 40% of the entire FY26 revenue.
Net Profit increased more than 10x YoY to ₹22.08 Lakhs from ₹2.11 Lakhs.
Other Expenses surged to ₹1.86 Cr in Q1 FY27, compared to ₹0.38 Cr in Q4 FY26 and ₹1.73 Cr in Q1 FY26.
Cost of materials consumed rose to ₹4.34 Cr, up from ₹2.21 Cr in the corresponding quarter of the previous year.
Earnings Per Share (EPS) stood at ₹0.47 for the quarter, up from ₹0.04 YoY.

💡 Investors should monitor if this elevated revenue run-rate is sustainable over the coming quarters and watch for any management commentary regarding the spike in 'Other Expenses' which impacted sequential margins.

Beryl Drugs Approves Q1 FY27 Results; TTM Revenue at Rs 19.31 Cr

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 11 Aug 2026, 05:06 PM

Beryl Drugs approved its unaudited financial results for the quarter ended June 30, 2026, in a board meeting held on August 11, 2026. The company, a micro-cap pharma player with a Rs 12 Cr market capitalization, also recorded the auditor's limited review report. Financial context shows the company had a TTM revenue of Rs 19.31 Cr and a thin net profit of Rs 0.42 Cr in FY26. Investors should track if the June quarter results show improvement over the volatile previous quarters where profits fluctuated between Rs -0.17 Cr and Rs 0.56 Cr.

Board meeting concluded at 05:00 P.M. on August 11, 2026
Approved unaudited financial results for the quarter ended June 30, 2026
TTM revenue stands at Rs 19.31 Cr with a 12.5% operating margin
Promoter holding marginally increased to 27.82% in June 2026 from 27.48% in March 2026

💡 Review the detailed Q1 FY27 P&L once published to assess if the company can sustain the Rs 0.56 Cr profit level seen in the March 2026 quarter.

Beryl Drugs to consider Q1 FY27 results on August 11, 2026

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 05 Aug 2026, 03:04 PM

Beryl Drugs Ltd has scheduled a board meeting for August 11, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of just Rs 11 Cr and reported a TTM revenue of Rs 19 Cr. Investors will be looking for a continuation of the profitability seen in the March 2026 quarter (Rs 0.56 Cr) following a volatile FY26. The promoter holding remains relatively low at 27.82%.

Board meeting scheduled for August 11, 2026, at 02:00 PM to approve Q1 results.
Trading window for insiders has been closed since July 1, 2026.
Company reported a net profit of Rs 0.56 Cr on revenue of Rs 5.47 Cr in the previous quarter (March 2026).
Promoter holding marginally increased to 27.82% in June 2026 from 27.48% in March 2026.

💡 Monitor the financial results on August 11 to assess if the company can maintain its operating margin, which stood at 12.5% for the trailing twelve months.

Beryl Drugs Reports Temporary Unavailability of Corporate Website Due to Technical Issue

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 21 Jul 2026, 01:05 PM

Beryl Drugs Ltd has informed the exchange that its official website, www.beryldrugs.com, is temporarily inaccessible due to an unexpected technical issue as of July 20, 2026. The company has initiated corrective measures with technical service providers to restore operations at the earliest. Management explicitly stated that there has been no impact on the company's business operations, financial systems, or statutory records. This is a minor administrative disruption for the micro-cap company, which has a market capitalization of Rs 11 Cr.

Website www.beryldrugs.com became temporarily unavailable due to technical issues reported on July 20, 2026
Management confirms zero impact on business operations, financial systems, or statutory records
Company is a micro-cap with a market capitalization of approximately Rs 11 Cr
TTM revenue for the company stands at Rs 19 Cr with a TTM PAT of Rs 0 Cr
Corrective measures were initiated immediately upon identifying the technical issue

💡 Investors should monitor the restoration of the website to ensure continued access to statutory disclosures. No financial or operational impact is expected from this event.

View All 524606 Announcements on Live Market Tracking →